

# ARO-AAT for Liver Disease in Alpha-1 Antitrypsin Deficiency: Clinical Development Progress

June 21, 2019


James C. Hamilton MD, MBA



# Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, without limitation, our developmental stage and limited operating history, our ability to successfully and timely develop products, enter into collaborations and achieve other projected milestones, rapid technological change in our markets, demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K, and other SEC filings discuss some of the important risk factors that may affect our ability to achieve the anticipated results, as well as our business, results of operations and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements. Additionally, Arrowhead disclaims any intent to update these forward-looking statements to reflect subsequent developments.

# Alpha-1 Antitrypsin Deficiency




# What is the Risk of Developing Liver Disease

Recent study on liver involvement in AATD (Clark et al., 2018)

- Evaluated 94 PiZZ AATD adult patients
- 35% demonstrated clinically significant ( $\geq$  F2) liver fibrosis based on biopsy
- Additionally, common medical conditions may further increase risk
  - Obesity
  - Hypertension
  - High cholesterol
  - Diabetes

# Arrowhead: RNAi-based therapeutics: *What is RNAi?*



## **RNAi = RNA interference**


- Normally, genes (DNA) transcribed into RNA which are translated into proteins
- RNAi inhibits the mRNA in a manner that is specific for a single gene
- **Not gene therapy or gene editing which may actually modify the genome**

# ARO-AAT: Mechanism of Action


ARO-AAT designed to stop Z-AAT production by silencing AAT gene expression to:

- Prevent liver accumulation of Z-AAT
- Allow clearance of accumulated Z-AAT protein
- Prevent cycles of cellular damage
- Prevent/Reverse progression of liver fibrosis

**PiZZ phenotype (diseased)**




**Pi null phenotype (normal liver)**



Feldmann G et al., *Gut* 1975

# Arrowhead RNAi Pipeline



Liver

Lung

Tumor

# ARO AAT1001 Clinical Study in Healthy Volunteers

## TWO PART STUDY

### DOUBLE BLIND

- 4 treatment arms
  - 35, 100, 200 and 300 mg
  - 100, 200, 300 mg **3 monthly doses**
  - 4 active, 4 placebo
- Assessments of safety, tolerability, plasma levels of ARO-AAT, plasma AAT changes


### UNBLINDED

- No placebo
- 3 groups
  - **Single doses** of 100, 200 and 300 mg of ARO-AAT
- Assessments of safety, tolerability, depth and duration of AAT reductions after a single dose

# ARO-AAT Phase 1, NHV Safety Summary

- 45 NHVs received at least 1 dose
- No serious or severe adverse events
- Mild injection site reactions in ~12% of injections (typically self limited, resolve in 48 hours)
- No dose related difference between active and placebo in lung function
- No adverse platelet/clotting related findings
- No adverse kidney findings

# ARO-AAT Phase 1, NHV SAD/MAD study



Supports quarterly or less frequent dosing

U.S. IND filed for Phase 2/3 ARO-AAT study

# ARO AAT2001 Phase 2 Study Design

**Phase:** Adaptive Phase 2/3 Study


**Location:** Multiple sites in UK, EU **and US**

**Study Design:**

- Multi-center, multi-dose, placebo-controlled, adaptive
- Drug: ARO-AAT Injection (ARO-AAT)      PLACEBO: 0.9% Normal Saline
- Route of administration: Subcutaneous Injection
  - Dosing on Days 1, 29 and 113 (and every 84 days thereafter in Part A, 6 doses every 84 days in Part B)

# ARO AAT2001 Study Design

**N=120 total, Randomization = 2:1 (active:placebo)**



\* All patients enrolled prior to Part B dose selection will be randomized to Part A cohorts and receive at least 3 doses at the Part A dose level before switching to Part B dose level. Only 1<sup>st</sup> 36 will require D113 biopsy.

Placebo patients will be rolled over to ARO-AAT at end of study

# ARO AAT2001 Study Objectives

## Primary Objectives (Part A):

- To select a single dose level for use in Part B of the study based on a combined evaluation of safety and pharmacodynamic dose response in each Part A dose

## Primary Objectives (Part B):

- To evaluate efficacy (as assessed by the proportion of ARO-AAT treated patients relative to placebo achieving a 2-point improvement in a histologic grading scale of alpha-1 antitrypsin deficiency associated liver disease AND no worsening of liver fibrosis based on end of study biopsy).

# ARO AAT2001 Key Inclusion/Exclusion Criteria


- Age 18-75 with PiZZ genotype AATD (study screening includes genotype)
- F2 or F3 (e.g. moderate to advanced) liver fibrosis
- Non-smoker
- No diagnosis of liver cirrhosis (at least not in this study)
- FEV1 < 65% predicted at Screening is exclusionary
- Augmentation use is allowed

# ARO AAT2001 Study Status

- Clearance from U.S. FDA and several European regulatory authorities to start study
- Sites opening in U.S./EU with plans to start screening patients next month

## In Conclusion.....

- While not as well historically characterized as lung disease, AATD Liver disease can be silently devastating
- Thanks largely to alpha-1 researchers and the Alpha-1 Foundation the importance of alpha-1 liver disease has been revealed
- AROAAT2001 is the first trial designed to potentially serve as a pivotal study for US approval
- The trial is FDA approved and centers should be open and enrolling in coming weeks



# ARO-AAT for Liver Disease in Alpha-1 Antitrypsin Deficiency: Clinical Development Progress

June 21, 2019

James C. Hamilton MD, MBA

